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Abstract
Background: For an effective bone graft for reconstruction of the maxillofacial region, an adequate vascular
network will be required to supply blood, osteoprogenitor cells, and growth factors. We previously reported that
the secretomes of bone marrow-derived mesenchymal stem cells (MSC-CM) contain numerous growth factors such
as insulin-like growth factor (IGF)-1, transforming growth factor (TGF)-β1, and vascular endothelial growth factor
(VEGF), which can affect the cellular characteristics and behavior of regenerating bone cells. We hypothesized that
angiogenesis is an important step for bone regeneration, and VEGF is one of the crucial factors in MSC-CM that
would enhance its osteogenic potential. In the present study, we focused on VEGF in MSC-CM and evaluated the
angiogenic and osteogenic potentials of MSC-CM for bone regeneration.
Methods: Cytokines in MSC-CM were measured by enzyme-linked immunosorbent assay (ELISA). Human umbilical
vein endothelial cells (HUVECs) were cultured with MSC-CM or MSC-CM with anti-VEGF antibody (MSC-CM + anti-VEGF)
for neutralization, and tube formation was evaluated. For the evaluation of bone and blood vessel formation with
micro-computed tomography (micro-CT) and for the histological and immunohistochemical analyses, a rat calvarial
bone defect model was used.
Results: The concentrations of IGF-1, VEGF, and TGF-β1 in MSC-CM were 1515.6 ± 211.8 pg/mL, 465.8 ± 108.8 pg/mL, and
339.8 ± 14.4 pg/mL, respectively. Tube formation of HUVECs, bone formation, and blood vessel formation were increased
in the MSC-CM group but decreased in the MSC-CM + anti-VEGF group. Histological findings suggested that new bone
formation in the entire defect was observed in the MSC-CM group although it was decreased in the MSC-CM + anti-VEGF
group. Immunohistochemistry indicated that angiogenesis and migration of endogenous stem cells were much more
abundant in the MSC-CM group than in the MSC-CM + anti-VEGF group.
Conclusions: VEGF is considered a crucial factor in MSC-CM, and MSC-CM is proposed to be an adequate therapeutic
agent for bone regeneration with angiogenesis.
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Background
Until recently, autogenous bone grafts including particulate
cancerous bone marrow (PCBM) and vascularized bone
grafts were considered the gold standard for the treatment
of bone defects in the maxillofacial region [1]. This well-
studied procedure has good prognosis but requires an extra
surgery at the donor site, which is an additional burden on
the patient. When the bone graft is performed, surgeons
have several requirements for the acquisition of blood
supply from the surrounding tissue, such as perforating the
cortical bone and preservation of the periosteum. These
points of attention are sometimes difficult because of the
conditions of the surrounding tissue after the surgery.
Several bone substitutes are commercially available;
however, these materials without a vascular network are
not suitable for larger bone defects due to insufficient
blood supply supporting the mesenchymal stem cells
(MSCs) and osteoblasts for bone repair and regeneration.
From these perspectives, novel bone reconstruction
procedures that enable regeneration of the vascular
network within the reconstructed area will be required.
Tissue engineering involves the generation of new tissue
from isolated cells with certain scaffolds and signaling
molecules [2]. Bone marrow-derived MSCs have been
extensively studied and used for various therapeutic
applications, especially bone regeneration [3]. MSCs
can be obtained using a minimally invasive technique,
and their use can obviate the need for donor site sur-
gery in autogenous bone graft procedures.
Recent studies have also revealed that implantation
of MSCs would contribute not only to pluripotency
but also to paracrine factors for the regeneration of
bone [4]. We have previously reported that the secre-
tomes of MSCs (MSC-CM) contain numerous cytokines
such as insulin-like growth factor (IGF)-1, transforming
growth factor (TGF)-β1, and vascular endothelial
growth factor (VEGF), which can affect the cellular
characteristics and behavior of regenerating bone cells
[5–7]. These secretomes will be released from the
implanted cells and will establish a new blood supply
via migration of endothelial cells to the sites of bone
defects and subsequent angiogenesis. Our previous
study reported that MSC-CM enhanced the migration
of MSCs, tube formation of human umbilical vein
endothelial cells (HUVECs), expression of osteogenic
and angiogenic markers of MSCs in vitro, and bone
and periodontal regeneration in vivo [8–10]. We
hypothesized that angiogenesis is an important step
for bone regeneration and that VEGF is a crucial
factor in MSC-CM that enhances its osteogenic
potential. In this study, we evaluated the angiogenic
and osteogenic potentials of MSC-CM for bone re-




All animal experiments undertaken in this study were
performed in strict accordance with the protocols ap-
proved by the Guidelines for Animal Experimentation of
the Nagoya University School of Medicine (approval
nos. 25,374 and 26,063). Human mesenchymal stem cells
(hMSCs) were purchased from Lonza, Inc. (Walkersville,
MD, USA) and cultured in MSC basal medium (Lonza,
Inc.) containing MSCGM SingleQuots (Lonza, Inc.) at
37 °C in 5% CO2 air. After primary culture, the cells
were subcultured at a density of approximately 1 × 104
cells/cm2. hMSCs at the third to sixth passages were
used for experiments.
Preparation of MSC-CM
hMSCs that were 80% confluent were re-fed with serum-
free Dulbecco’s modified Eagle medium (DMEM(−)) con-
taining antibiotic-antimycotic solution. The cell-cultured
conditioned medium was collected after 48 h of incubation.
The collected cultured conditioned medium was defined as
MSC-CM and was stored at −80 °C before being used for
the following experiments.
For the tube formation assay, MSC-CM was then con-
centrated and stored as described. Briefly, MSC-CM was
centrifuged for 5 min at 407 g and then for another 3 min
at 1630 g to remove any cells. Five milliliters of MSC-CM
was mixed with 45 mL of 100% ethanol and incubated at
−20 °C for 1 h. The mixture was centrifuged for 15 min at
24,229 g at 4 °C, and the supernatant was discarded. The
precipitate was suspended again in cold 90% ethanol and
centrifuged for 15 min at 24,229 g at 4 °C. The final
precipitate was frozen at −80 °C, lyophilized, and stored at
−80 °C until use.
When the tube formation assay was performed, this
frozen precipitate was dissolved with optimized angio-
genesis medium (AM) at the same concentration of
MSC-CM. The concentrations of each growth factor
after freeze-thawing did not show significant differences
by an enzyme-linked immunosorbent assay (ELISA)
(data not shown).
Enzyme-linked immunosorbent assay (ELISA)
The concentrations of IGF-1, VEGF, and TGF-β1 in MSC-
CM were investigated using a Human Quantikine ELISA
kit (R&D Systems, Hornby, Ontario, Canada) according to
the manufacturer’s instructions. Briefly, 200 mL of MSC-
CM, DMEM-0%FBS, or DMEM-30%FBS was added to
96-well microplates that were coated with a monoclonal
antibody to the factor of interest and incubated for 2 h.
After washing with phosphate-buffered saline (PBS), a
horseradish peroxidase-conjugated cytokine or growth
factor-specific antibody was added to each well, incubated
for 2 h, and washed. Substrate solution was added and
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incubated for 30 min, and the reaction was terminated by
addition of stop solution. Cytokine/growth factor levels
were determined by measurement of the optical density at
450 nm, using a microplate spectrophotometer (Power-
Scan4; DS Pharma Biomedical, Osaka, Japan).
Neutralizing antibodies to VEGF
MSC-CM was combined with neutralizing antibodies
from a commercial source (R&D Systems) against VEGF
(MAB293). The final concentration of the antibodies
was 10 μg/mL and, therefore, was 100-fold greater than
the concentration for half-maximal inhibition of 10 ng/
mL of the recombinant proteins (R&D Systems).
Tube formation assay
An angiogenesis assay kit (KZ-1000; Kurabo, Osaka, Japan)
was used according to the manufacturer’s instructions [11].
This kit comprised a 24-well culture dish in which
HUVECs and human diploid fibroblasts were seeded in the
optimal conditions for capillary tube formation. The opti-
mized AM in each well was changed on days 1, 4, 7, and 9
with fresh medium containing VEGF (10 ng/mL), MSC-
CM, MSC-CM + anti-VEGF antibody, or none. After
11 days, cells were fixed in 70% ethanol and incubated with
diluted primary antibody (mouse anti-human CD31,
1:4000) for 1 h at 37 °C and with secondary antibody (goat
anti-mouse immunoglobulin (Ig) G alkaline phosphatase-
conjugated antibody, 1:500) for 1 h at 37 °C, and
visualization was achieved using 5-bromo-4-chloro-3-indo-
lyl phosphate/nitro blue tetrazolium. Images were obtained
from five different fields (5.5 mm2/field) for each well, and
tube length (the total lengths of the tubes) and joints (the
number of capillary connections) were quantified using the
Angiogenesis Image Analyzer Ver.2 (Kurabo).
Rat calvaria bone defect model
Ten-week-old male Wistar/ST rats (n = 24) were anesthe-
tized by intraperitoneal injection of pentobarbital (Somno-
pentyl®; Kyoritsu Seiyaku, Tokyo, Japan) (20 mg/kg body
weight). For the evaluation of bone formation with micro-
computed tomography (micro-CT) and histological and
immunohistochemical assessments, two circular bone
defects (5 mm in diameter) were made in calvarial bone.
However, for the evaluation of bone and blood vessel for-
mation with micro-CT, an 8-mm defect was created. Each
defect was created using a dental surgical drilling unit with
a trephine constantly cooled with sterile saline; subse-
quently, the calvarial bone was carefully removed to avoid
tearing of the dura. After thoroughly rinsing with saline to
wash out any bone fragments, the experimental materials
were implanted into the defects.
Atelocollagen (Terudermis®; Olympus Terumo Bioma-
terials, Tokyo, Japan), which was cut into the desired
form, was suspended in MSC-CM, MSC-CM + anti-
VEGF antibody, or PBS, respectively; the following
groups were defined: (1) MSC-CM: MSC-CM/Teruder-
mis®; (2) MSC-CM + antiVEGF: MSC-CM + anti-VEGF
antibody/Terudermis®; (3) PBS: PBS/Terudermis®; (4)
Defect: unfilled defect.
Then, the periosteum and scalp were closed with
interrupted 4–0 nylon sutures.
Microfil perfusion
All 8-mm defect samples were perfused with Microfil
(Flowtech, Carver, MA, USA) after euthanasia to evaluate
blood vessel formation as previously described [12].
Briefly, the chest was shaved and an incision was made
from the front limbs down to the xiphoid process. Scissors
were used to cut along one side of the sternum, and the
rib cage was retracted laterally. The descending aorta was
clamped, and an angiocatheter was used to penetrate the
left ventricle. The inferior vena cava was incised, and
immediately after, perfusion of 20 mL of heparinized
saline was started (100 U/mL at 2 mL/min using a syringe
pump). A solution of Microfil was prepared in a volume
ratio of 4:5 of Microfil:diluent with 5% curing agent.
Following perfusion with saline, 20 mL of the Microfil
solution was perfused at a rate of 2 mL/min. Finally, the
Microfil was allowed to set overnight at 4 °C.
Radiographic and histological analyses
Surgical sites were dissected, fixed in 4% PFA, and sub-
jected to micro-CT analysis using a laboratory X-ray CT
device (Rigaku, Tokyo, Japan). Using the software supplied
with the instrument, three-dimensional (3D) images were
reconstituted. After radiographical assessment, explants
were decalcified using K-CX solution (Falma Co., Tokyo,
Japan) and were then dehydrated using graded ethanol,
cleared with xylene, and embedded in paraffin. The speci-
mens were cut in a sagittal direction to make 5-μm-thick
histological sections in the buccal-palatal plane and were
stained with hematoxylin and eosin. Histological analysis
was performed by light microscopy (CK40; Olympus).
Immunohistochemical analyses
All 4-mm defect samples were collected after 2 weeks.
Fresh-frozen sections of these samples were made accord-
ing to the Kawamoto’s method, using a Multi-Purpose
Cryosection Preparation Kit [13]. Cryofilm type 2C was
applied to the cutting surface of the completely frozen
block, which was cut with a tungsten carbide knife at
−25 °C in a cryostat chamber (Leica CM3050S; Leica
Microsystems). The section was fixed with 100% ethanol
for 10 min and then washed with PBS for 3 min. CD31, a
monoclonal mouse antibody (BD Biosciences, San Jose,
CA, USA), was used as a marker for rat endothelial cells.
CD105, a polyclonal rabbit antibody (Santa Cruz Biotech-
nology, Inc., Dallas, TX, USA), was used as a marker for
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rat stem cells. FLK-1, a monoclonal mouse antibody
(Santa Cruz Biotechnology), was used as a marker for
VEGF-R2. Alexa Fluor 633 conjugated goat anti-mouse
IgG (Thermo Fisher Scientific, Waltham, MA, USA) and
Alexa Fluor 488 conjugated donkey anti-rabbit IgG
(Thermo Fisher Scientific) were used as secondary
antibodies. After 4′,6-diamidino-2-phenylindole staining,
the section was washed with PBS and mounted between a
glass slide and the adhesive film. The section was enclosed
by mounting the resin SCMM R2 on the glass slide, and
the resin was hardened with ultraviolet (UV) irradiation
for 1 min by means of the UV Quick Cryosection
Mounter (ATTO Bio-Instrument). After fixation, the
specimen was observed by fluorescence microscopy
(BZ9000; Keyence Co., Osaka, Japan).
Statistical analysis
All experiments were conducted in triplicate and
repeated at least twice. Group means and standard
deviations were calculated for each measured param-
eter. Statistical differences were evaluated with
Tukey’s honestly significant difference (HSD) test.
Statistically, a value of p < 0.05 was considered signifi-
cant; p < 0.01, very significant.
Results
Growth factors included in MSC-CM
In MSC-CM, the concentrations of IGF-1, VEGF, and
TGF-β1 were 1515.6 ± 211.8 pg/mL, 465.8 ± 108.8 pg/
mL, and 339.8 ± 14.4 pg/mL, respectively. After neutral-
izing MSC-CM by anti-VEGF antibody, the inclusion of
VEGF in MSC-CM was below the detection limits by
ELISA, whereas there were no significant differences in
the concentrations of the other factors.
Effect of VEGF in MSC-CM on tube formation of HUVECs
In the presence of AM and AM with anti-VEGF,
HUVECs did not demonstrate tube formation. In
contrast, AM with MSC-CM or VEGF-stimulated tube
formation (Fig. 1a). The tube lengths were 18341.6 ±
3453.1 pixels, 20987.5 ± 2054.0 pixels, 11244.4 ±
1662.1 pixels, and 11542.3 ± 1870.0 pixels in AM with
MSC-CM, in AM with VEGF, in AM with MSC-CM +
anti-VEGF, and in AM only, respectively (Fig. 1b). The
number of joints were 72.4 ± 20.7, 81.8 ± 15.9, 42.7 ±
15.3, and 38.1 ± 12.4, respectively (Fig. 1c). The tube
lengths and the number of joints were significantly
greater in AM with MSC-CM than in AM with MSC-
CM + anti-VEGF or in AM only (p < 0.05).
A B
C
Fig. 1 The secretomes of bone marrow-derived mesenchymal stem cells (MSC-CM) promoted tube formation of HUVECs. a Tube formation of
HUVECs was compared in AM, and in AM with MSC-CM, VEGF (10 ng/mL), and MSC-CM plus anti-VEGF antibody (10 μg/ml). After 11 days, developing
new blood vessels were observed under a microscope and photographed. AM with MSC-CM or EGF stimulated tube formation (scale bar: 500μm).
b The total length of blood vessels was analyzed using angiogenesis-measuring software. c The number of capillary connections was also analyzed.
There were statistically significant differences between the lengths of blood vessels in the MSC-CM group and those in the other groups although
there was no significant difference in the number of joints between MSC-CM and MSC-CM plus anti-VEGF group. (n = 10 for each group). Data are
presented as mean ± standard deviation. *P < 0.05, **P < 0.01
Katagiri et al. Maxillofacial Plastic and Reconstructive Surgery  (2017) 39:8 Page 4 of 8
Neutralization of VEGF reduced bone and blood vessel
formation by MSC-CM in vivo
We evaluated the area of newly formed bone as a percen-
tage of the total graft area of 5-mm defect samples at
2 weeks after implantation, using micro-CT scanning
(Fig. 2a, a–d). The area of newly formed bone in the
MSC-CM group (72.3 ± 17.1%) was significantly increased
compared with that in the Defect (22.2 ± 8.0%), PBS (30.9
± 6.2%), and MSC-CM + anti-VEGF (33.1 ± 12.4%) groups
(p < 0.05). There were no significant differences between
the MSC-CM + anti-VEGF group and other controls (De-
fect and PBS groups) (Fig. 2b). We then evaluated the
blood vessel formation in 8-mm defect samples using
Microfil and micro-CT scanning at 2 weeks after
implantation (Fig. 2a, e–h). New bone and blood vessel
volumes in the MSC-CM group (62.1 ± 6.0%) were signifi-
cantly increased compared with that in the Defect (37.5 ±
1.6%), PBS (43.5 ± 10.0%), and MSC-CM + anti-VEGF
(42.4 ± 4.5%) groups (p < 0.05). Moreover, new bone
formation was confirmed along the newly formed blood
vessel in the MSC-CM group, although newly formed
blood vessels in other groups were fewer with less bone
formation (Fig. 2c).
Histological analysis also showed well-regenerated
bone in the MSC-CM group compared with the other
groups. The bone defect was almost covered with newly
regenerated bone in the MSC-CM group in contrast to
other groups, where much connective tissue had covered
A
a b c d
e f g h
B C
Fig. 2 Radiographic evaluation of new bone and blood vessel formation in rat calvaria bone defect. a Bone formation was evaluated with 5-mm
defect samples (a-d), and bone and blood vessel formation was evaluated with 8-mm defect samples (e-d). (a, e) Defect group, (b, d) PBS group,
(c, g) MSC-CM group, and (d, h) MSC-CM + anti-VEGF group. The MSC-CM group showed increased bone and blood vessel formation compared
with the other groups (c, g). New bone formation in the MSC-CM group was seen along the newly formed blood vessel (g). Neutralization with
anti-VEGF antibody remarkably decreased bone and blood vessel formation (d, h). Percentage of bone formation b and bone and blood vessel
formation c. In the MSC-CM group, both new bone formation and blood vessel formation were significantly increased compared to the other
groups, and neutralization with anti-VEGF antibody remarkably decreased bone and blood vessel formation with no statistical differences
compared with the Defect and PBS groups. *p < 0.05
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the defect. Histological findings also suggested that the
new bone formation was reduced in the MSC-CM +
anti-VEGF group (Fig. 3).
Neutralization of VEGF-reduced endogenous stem cell
and endothelial cell migration in vivo
Immunohistochemical staining showed that numerous
CD31-, CD105-, or FLK-1-positive cells were present
throughout the specimen in the MSC-CM group. In
MSC-CM + anti-VEGF, PBS, and Defect groups, fewer
CD31-, CD105-, or FLK-1-positive cells were seen
(Fig. 4).
Discussion and conclusions
When considering successful reconstruction of bone,
angiogenesis of the grafted bone or bone substitutes
A B
C D
Fig. 3 Histologic views of newly formed bone in 5-mm defect samples. a MSC-CM group, b MSC-CM + anti-VEGF group, c PBS group, and d
Defect group. The left image in each group is shown at low magnification (×12.5) and the right image shows a high magnification (×200) view of
the framed area of the left image. Hematoxylin and eosin staining was performed. In the MSC-CM group, the defect was filled with newly formed
bone although the defects were filled with fibrous connective tissue with a residual collagen scaffold in other groups. In the MSC-CM + anti-VEGF
group, the defect was almost covered with fibrous connective tissue and fewer newly formed bone was observed at the cutting edge of
the defect
Fig. 4 Immunohistochemical staining of the defects in 5-mm defect samples. In the MSC-CM group, many CD31-positive cells (red) are seen in
the defect. FLK-1-positive cells are arranged in a circular shape and CD105-positive cells (green) are observed near the CD105-positive cells. From
the hematoxylin and eosin (H-E) images of the MSC-CM group, these CD31 and FLK-1-positive cells were considered to form the blood vessels. In
the MSC-CM and MSC-CM + anti-VEGF groups, few CD31-, FLK-1-, and CD105-positive cells were seen in the specimens
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including alloplastic and biocompatible materials is im-
portant. An abundant blood supply allows the endogenous
cells and growth factors to migrate to the bone defect
[14]. On the other hand, MSCs play an important role in
bone defects, not only because of their multipotency but
also as a source of cytokine supply [5, 6, 15]. Furthermore,
blood clots and hypoxia of the grafted area induce the
release of several cytokines from the stem cells and
blood cells via paracrine signaling [16–19]. From
these perspectives, secretomes of MSCs and angiogen-
esis were considered as the key factors for successful
reconstruction of bone.
In the present study, we focused on VEGF involved in
MSC-CM. We have reported that MSC-CM contains
cytokines such as IGF-1, VEGF, and TGF-β1, which may
synergistically affect migration, angiogenesis, and osteo-
genic differentiation of host MSCs [5, 6, 9, 10]. The effects
of these three cytokines are thought to be very complex,
although IGF-1 is believed to regulate the migration of
osteoblasts [20] and MSCs [21], and sustained systemic or
local infusion of IGF-1 was shown to enhance bone
formation [22], while TGF-β1 stimulates migration of
osteoprogenitor cells and regulates cellular proliferation,
differentiation, and production of extracellular matrix
[23]. VEGF is a master regulator of angiogenesis and
enhances survival and differentiation in endothelial cells,
which promotes osteogenesis [24]. Cooperative effects
that these cytokines exert on each other have also been
reported. IGF-1 upregulates VEGF expression via hypoxia-
inducible factor-2a [25]. TGF-β upregulates the synthesis
of VEGF in endothelial cells [26]. These facts suggested
that the osteogenesis by MSC-CM was synergetic, and
VEGF is thought to be one of the crucial factors in MSC-
CM that enhanced the osteogenic potential of MSC-CM.
The effects of neutralization of VEGF by anti-VEGF
antibody were as expected. Tube formation of HUVEC
induced by MSC-CM was significantly reduced by the
presence of anti-VEGF antibody (Fig. 1). Micro-CT images
showed that the blood vessels that formed within the bone
defects were also reduced (Fig. 2). Micro-CT images also
indicated that the bone formation newly induced by MSC-
CM was seen along the blood vessels within the bone
defects and anti-VEGF antibody eliminated these effects
of MSC-CM on bone formation (Fig. 2). Histological find-
ings revealed that anti-VEGF antibody treatment inhibited
bone formation and that the defect was almost filled with
the fibrous connective tissue with a residual collagen
scaffold (Fig. 3). CD31- and FLK-1-positive cells were
increased in the MSC-CM group, whereas such cells were
fewer in number in the MSC-CM + anti-VEGF group,
indicating the contribution of VEGF in MSC-CM to
angiogenesis. Interestingly, CD105- and FLK-1-positive
cells were seen within the stroma along the newly formed
bone in the MSC-CM group (Fig. 4). These findings
suggested that the endogenous stem cells migrated via the
newly formed blood vessels and contributed to bone for-
mation in the MSC-CM group. Thus, it was considered
that neutralization of VEGF suppressed the angiogenesis
that caused less migration of endogenous stem cells into
the defect and less new bone formation.
In our previous study [27, 28], a cocktail of recombinant
human IGF-1, VEGF-A, and TGF-β1 was prepared using
concentrations similar to those in MSC-CM. Conversely,
these cytokines were depleted from MSC-CM, and the
effects of the cocktail, MSC-CM, and the cytokine-
depleted conditioned medium on bone regeneration were
evaluated. The cytokine cocktail and MSC-CM, but not
cytokine-depleted medium, increased bone regeneration
in rat calvarial bone defects. Furthermore, according to
our preliminary study, this cocktail promoted bone regen-
eration with more than double combinations of growth
factors without VEGF in the cytokine cocktail such as
IGF-1 plus TGF-β1. These findings strongly indicated that
the combination of these three growth factors was effect-
ive and VEGF was thought to be one of the crucial factors
in MSC-CM and for bone regeneration.
From the results of this study, we found that VEGF in
MSC-CM enhanced the migration of endogenous endo-
thelial and stem cells, which enabled the formation of
more blood vessels and bone tissue in the bone defect.
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